Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Manuela Bratti
Institutions:
Centre National de la Recherche Scientifique,
Inserm,
Université Paris Cité,
Centre de Recherche sur l'Inflammation,
Institut de l'Audition
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Université Paris Cité,
Sorbonne Paris Cité,
Centre de Recherche sur l'Inflammation,
Université Paris Diderot,
Institut de l'Audition
show all 7
ORCID:
0000-0002-4658-318X
Observed ORCID:
0000-0002-4658-318X
OpenAlex ID:
A5000150369
Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond
2022
·
Joana Vitte
, Shamila Vibhushan
, et al.
·
Medical Principles and Practice
·
128
PDF
Cytoskeletal Transport, Reorganization, and Fusion Regulation in Mast Cell-Stimulus Secretion Coupling
2021
·
Gaël Ménasché
, Cyril Longé
, et al.
·
Frontiers in Cell and Developmental Biology
·
44
PDF
TLR4 Receptor Induces 2-AG–Dependent Tolerance to Lipopolysaccharide and Trafficking of CB2 Receptor in Mast Cells
2019
·
Zyanya P Espinosa-Riquer
, Alfredo Ibarra-Sánchez
, et al.
·
The Journal of Immunology
·
33
Mast Cell Chymase and Kidney Disease
2020
·
Shamila Vibhushan
, Manuela Bratti
, et al.
·
International Journal of Molecular Sciences
·
24
PDF
INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
·
Molecular Cancer Therapeutics
·
13
Rab44 regulates murine mast cell–driven anaphylaxis through kinesin-1–dependent secretory granule translocation
2022
·
Cyril Longé
, Manuela Bratti
, et al.
·
Journal of Allergy and Clinical Immunology
·
13
Insulin-regulated aminopeptidase contributes to setting the intensity of FcR-mediated inflammation
2022
·
Manuela Bratti
, Shamila Vibhushan
, et al.
·
Frontiers in Immunology
·
7
PDF
Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S5 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S7 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Table 1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Table 2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Table 3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2026
·
Manuela Bratti
, Elisa Stubbs
, et al.
Complex mast cell CCL2–chemokine trafficking patterns during local allergic responses
2026
·
Juan Eduardo Montero-Hernández
, Shamila Vibhushan
, et al.
·
Journal of Allergy and Clinical Immunology
Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Table 1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
PDF
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S5 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024
·
Manuela Bratti
, Elisa Stubbs
, et al.
Show more works
View as search
Works count:
37
Citation count:
261
H-index:
7
I10-index:
6
Year
Topic
Type